Cancer
Malignant Cervical Neoplasm
CI-CAN-00007992Explore in graph →
Top-level506 active trials4 approved drugs14 evidence items
Loading cancer entity…
Cancer
CI-CAN-00007992Explore in graph →
Clinical trials
1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04708470 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05021237 | Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer | completed | Phase 2 | 12 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 17, 2026 |
| clinicaltrials |
| NCT02880007 | Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer(TRIDICOL) | completed | Phase 2 | 48 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04432597 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | completed | Phase 1 / Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03495882 | A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | completed | Phase 1 / Phase 2 | 175 | Agenus Inc.INDUSTRY | 9 | Aug 11, 2026 | clinicaltrials |
| NCT04719273 | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | completed | Phase 2 | 14 | Thomas Jefferson UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03180294 | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | completed | Phase 2 | 230 | NRG OncologyOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03612791 | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab(ATEZOLACC) | completed | Phase 2 | 189 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04300647 | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer(SKYSCRAPER-04) | completed | Phase 2 | 172 | Hoffmann-La RocheINDUSTRY | 17 | Mar 12, 2026 | clinicaltrials |
| NCT04341883 | Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT00957411 | Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer(CETUXICOL) | completed | Phase 2 | 76 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT01676818 | Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer | completed | Phase 2 | 32 | University of Southern CaliforniaOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT01935934 | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 2 | Oct 1, 2025 | clinicaltrials |
| NCT03298893 | Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)(NiCOL) | completed | Phase 1 / Phase 2 | 21 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04646005 | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy | completed | Phase 2 | 113 | Regeneron PharmaceuticalsINDUSTRY | 8 | Sep 8, 2025 | clinicaltrials |
| NCT00924027 | A Study of Patients Receiving High-Dose Rate Brachytherapy | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03300557 | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03104699 | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer | completed | Phase 1 / Phase 2 | 211 | Agenus Inc.INDUSTRY | 9 | Jul 30, 2025 | clinicaltrials |
| NCT03444376 | The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer | completed | Phase 1 / Phase 2 | 65 | Genexine, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03086681 | Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma(ECWHCCFLACC) | completed | Phase 2 | 120 | Yong Zhang,MDOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT02635360 | Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer | completed | Phase 2 | 94 | Linda R DuskaOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03357757 | Avelumab With Valproic Acid in Virus-associated Cancer(LATENT) | completed | Phase 2 | 39 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02684227 | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04380805 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer | completed | Phase 2 | 30 | AkesoINDUSTRY | 3 | Feb 28, 2025 | clinicaltrials |
| NCT04951921 | Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy | completed | Phase 2 | 6 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04275713 | Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC(METOXY-LACC) | completed | Phase 2 | 41 | Oslo University HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT03946358 | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)(VolATIL) | completed | Phase 2 | 47 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT01554397 | Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer | completed | Phase 2 / Phase 3 | 101 | University of California, San DiegoOTHER | 6 | Nov 29, 2024 | clinicaltrials |
| NCT05227651 | AK104 in Neoadjuvant Treatment of Cervical Cancer | completed | Phase 2 | 14 | AkesoINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT02040142 | HIPEC for Peritoneal Carcinomatosis | completed | Phase 2 | 51 | Albert Einstein College of MedicineOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)(DICE) | completed | Phase 2 | 134 | Imperial College LondonOTHER | 2 | Sep 20, 2024 | clinicaltrials |
| NCT04799639 | Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer | completed | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT01088347 | Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer | completed | Phase 1 / Phase 2 | 9 | University Medical Center GroningenOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03476798 | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium(Clovis-001) | completed | Phase 2 | 49 | University of OklahomaOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06226350 | A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma | completed | Phase 2 | 29 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jan 26, 2024 | clinicaltrials |
| NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | completed | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04590599 | A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy | completed | Phase 2 | 205 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04405349 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | completed | Phase 2 | 52 | Nykode Therapeutics ASAINDUSTRY | 6 | Dec 15, 2023 | clinicaltrials |
| NCT04542356 | Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer | completed | Phase 2 | 60 | Chongqing University Cancer HospitalOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials